2 completed, 1 recruiting, 1 terminated. 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 2, Recruiting 1, Terminated 1 |
Follow Dysplasia: new trials by email Literature Review of Dysplasia trials Research Report on Dysplasia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of VEGF-A Targeting NIR-II Fluorescence Endoscopy in the Gastrointestinal Tract Bev-ICG, NIR-II fluorescence endoscopy platform - Gastrointestinal Carcinoma, Dysplasia | Phase 1 | Recruiting | Institute of Automation, Chinese Academy of Sciences | 30 | 2023-07-20 | 2025-05-13 |
| VEGF-targeted Fluorescence Near-Infrared (NIR) Endoscopy in (Pre)Malignant Esophageal Lesions Bevacizumab-IRDye800CW, Near infrared fluorescence endoscopy platform - Esophageal Cancer, Dysplasia | Phase 1 | Completed | University Medical Center Groningen | 14 | 2014-04-01 | 2024-04-16 |
| A Trial of Photodynamic Therapy With HPPH for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Oral Cavity and/or Oropharynx HPPH - Dysplasia, Carcinoma of the Oral Cavity | Phase 1 | Completed | Roswell Park Cancer Institute | 29 | 2010-06-08 | 2018-10-16 |
| Erlotinib Hydrochloride in Preventing Cancer in Patients With Precancerous Lesions of the Lung Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study - Dysplasia, Metaplasia | Phase 1 | Terminated | National Cancer Institute (NCI) | 60 | 2009-10-01 | 2015-02-18 |
Esophageal Neoplasms (1) · Metaplasia (1) · Mouth Neoplasms (1) · Oropharyngeal Neoplasms (1)
Head and Neck Neoplasms (2) · Neoplasms (2) · Neoplasms by Site (2) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Esophageal Diseases (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Mouth Diseases (1) · Otorhinolaryngologic Diseases (1) · Otorhinolaryngologic Neoplasms (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Pharyngeal Diseases (1) · Pharyngeal Neoplasms (1)
2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a (1) · Erlotinib Hydrochloride (1)
Institute of Automation, Chinese Academy of Sciences (1) · National Cancer Institute (NCI) (1) · Roswell Park Cancer Institute (1) · University Medical Center Groningen (1)
United States (2) · China (1) · Netherlands (1)
Frans TM Peters, MD PhD (1) · Hassan Arshad, MD (1) · Seema Khan (1) · Wouter B Nagengast, PharmD MD PhD (1)
N01CN35157 (1), P30CA060553 (1)